SCHEMBL5509867

SCHEMBL5509867

CCOC(=O)c1nn(C(=O)OC(C)C)nc1C(=O)c1cc(OC)c(OC)cc1N

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.40
MAPT P10636 4/20 0.36
DPP4 P27487 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 5/20 0.36
MAPK1 P28482 2/20 0.36
HPGD P15428 2/20 0.35
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTR4 Q13639 1/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 1/20 0.35
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.34
MYC P01106 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5508711 0.85 KDM4E (0.38) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5510324 0.84 LMNA (0.45) KDM4EMAPTLMNAALDH1A1GAA
SCHEMBL5511474 0.83 KDM4E (0.40) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL4708030 0.83 KDM4E (0.37) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5512817 0.83 KDM4E (0.42) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5512916 0.83 KDM4E (0.44) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5511556 0.81 KDM4E (0.40) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5518587 0.80 MAPT (0.38) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5524774 0.80 KDM4E (0.43) KDM4EMAPTDPP4LMNAALDH1A1
SCHEMBL5515229 0.79 KDM4E (0.37) KDM4EMAPTDPP4LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 US disclosed
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1026167-B1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS MEIJI SEIKA KAISHA (JP) 2003-03-05 EP disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 KDM4E 752/4885MAPT 3031/4885DPP4 719/4885
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 KDM4E 547/4885MAPT 3223/4885DPP4 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.